PRT 2527
Alternative Names: PRT-2527Latest Information Update: 14 Jun 2025
At a glance
- Originator Prelude Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 9 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome; T-cell lymphoma
- Preclinical Marginal zone B-cell lymphoma
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2025 PRT 2527 has patent protection worldwide
- 25 Apr 2025 Preclinical trials in Marginal zone B-cell lymphoma in USA (unspecified route), prior to April 2025
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Marginal zone B-cell lymphoma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)